Drug intelligence / Profile preview

4ET2104

Development stage: Preclinical
Lead developer: 4E Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

4ET2104 is a peripherally restricted small molecule inhibitor of MAP kinase-interacting kinase (MNK), developed by 4E Therapeutics for the treatment of migraine pain. By targeting the MNK-eIF4E signaling pathway, the drug aims to modulate protein synthesis associated with pain signaling without crossing the blood-brain barrier, thereby reducing central nervous system-related side effects. It is currently in IND-enabling studies and serves as a backup compound to the company's lead candidate, 4ET2124.

Targets

MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)MKNK2 (MAP kinase-interacting serine/threonine-protein kinase 2)

Beyond the preview

Go deeper on 4ET2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4ET2104.

Explore the full profile